|
⚲
|
| Keyboard |
| Stonepine Capital Management LLC
✚
|
|
|---|---|
| CRD # | 139891 |
| SEC # | 801-136874 |
| CIK # | 0001370042, 0001440771 |
| AUM | 181.0 M (2026-06-26) |
| Employees | 4 (75% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 541-647-5673 |
| Address | 2900 NW Clearwater Drive Bend, OR 97703 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($M) |
|---|
| Fees and Compensation — Form ADV Part 2A (6/26/2026) [Brochure] |
|---|
Item 5. Fees and Compensation Stonepine’s compensation is negotiable and varies, but typically it charges a 2% annual management fee with respect to each investor in Stonepine Capital, payable in quarterly installments at the beginning of each calendar quarter based on the net market value of each investor’s capital account on that date. Stonepine also typically receives a performance-based allocation with respect to each investor in Stonepine Capital equal to 20% of net profits (including both realized and unrealized gains and losses) otherwise allocable to such investor. Performance allocations are made with respect to each investor at the end of each calendar year (and on withdrawals or redemptions with respect to the amount withdrawn or redeemed), and are typically only applied to the portion of profits that exceed the cumulative losses previously allocated to that investor in that year or in any subsequent year. Stonepine may waive or reduce all or part of the management or performance-based allocations with respect to any investor or Fund. For example, Stonepine has waived or reduced the management fee and performance-based allocations for certain strategic investors in Stonepine Capital and for certain employees and family members. In addition, an SPV may be subject to lower management fees and performance-based allocations than Stonepine Capital. Please see Item 6 below for additional information regarding Stonepine’s receipt of performance-based allocations. Stonepine typically deducts management fees and performance allocations directly from the Funds. Stonepine believes that its fees are competitive with fees charged by other investment advisers for comparable services. Comparable services may be available, however, from other sources for lower fees. The disclosure in this Item 5, together with the disclosure in Item 12, allow a plan that is subject to the Employee Retirement Income Security Act of 1974 and that invests in an investment limited partnership of which Stonepine is general partner, to use the “alternative reporting option” to report Stonepine’s compensation as “eligible indirect compensation” on the Schedule C of the plan’s Form 5500 Annual Return/Report of Employee Benefit Plan. Relationships with each Fund are terminable on expiration of the Fund’s term, its dissolution or the termination of Stonepine as the investment adviser to the Fund. Generally, each investor may withdraw from Stonepine Capital on specified prior written notice, on the last day of any calendar quarter. If an investor in Stonepine Capital makes a withdrawal before the day preceding the first anniversary of the capital contribution to which the withdrawn amount relates, that investor must pay Stonepine Capital a withdrawal fee of 5% of the amount withdrawn (as detailed in Stonepine Capital’s governing documents). An investor who withdraws from a Fund on a date other than the last day of a quarter does not receive a refund of the management fee previously paid. Investors in an SPV may be subject to more favorable liquidity provisions than Stonepine Capital. Each Fund is responsible for its own costs and expenses, including trading costs and expenses (such as brokerage commissions, expenses related to short sales, and clearing and settlement charges), research expenses, ongoing legal, audit, bookkeeping fees and expenses, and the fees and expenses charged by the Fund’s administrator and sub-administrator for their accounting, bookkeeping and other services. Stonepine allocates any expenses that relate to multiple Funds among all of those Funds as it deems appropriate in its reasonable discretion. Stonepine bears its own operating, general, administrative and overhead costs and expenses, other than the expenses described in the preceding two paragraphs. All or part of these costs and expenses may be paid, however, by securities brokerage firms that execute the Funds’ securities trades, as discussed in Item 12 below. |
| Account Minimums and Types of Clients — Form ADV Part 2A (6/26/2026) [Brochure] |
|---|
Item 7. Types of Clients Stonepine provides investment advice solely to investment funds. Investors in the Funds generally are required to invest a minimum of $500,000, but Stonepine may waive, and has waived, this minimum. Investors must be (i) “accredited investors” for purposes of Regulation D under the Securities Act, and (ii) “qualified purchasers” as defined in Section 2(a)(51) of the Investment Company Act. |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Verastem Inc | 17.5 | ||
| R&R Acquisition VI Inc | 17.0 | ||
| Oxygen Biotherapeutics Inc | 15.6 | ||
| Evolus Inc | 9.0 | ||
| Camp4 Therapeutics Corp | 6.1 | ||
| Nektar Therapeutics | 6.1 | ||
| Kempharm Inc | 4.5 | ||
| Access Pharmaceuticals Inc | 3.8 | ||
| Corbus Pharmaceuticals Holdings Inc | 3.6 | ||
| Establishment Labs Holdings Inc | 3.2 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Metolius Capital LP | [2017-03-30] | 7.9 M | 2.6 M |
| Filed 2018-12-06 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $500,000 · Remaining Indefinite · Duration More than one year · Finder's Fee $18,645 · Net Assets Decline to Disclose | ||||
| HF | Tumalo Capital LP | [2017-03-30] | 7.6 M | 2.5 M |
| Filed 2018-12-06 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $500,000 · Remaining Indefinite · Duration More than one year · Finder's Fee $23,449 · Net Assets Decline to Disclose | ||||
| HF | Stonepine Capital LP | 2015-03-24 | 181.0 M | |
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 1 | 181.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 1 | 181.0 |
| By Discretionary | ||
| Discretionary | 1 | 181.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 1 | 181.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 181.0 | |
| Total | 1 | 181.0 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Timothy Lynch | Executive Officer | 7 | 2 | |
| Matt Carroll | Executive Officer | 4 | 2 | |
| Jon Plexico | Executive Officer | 3 | 2 | |
| Stonepine Capital Management LLC | Executive Officer | 3 | 2 | |
| Jeff Nunnenkamp | Executive Officer | 3 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001370042] | |
| 4 | [0001370042] | |
| SC 13D | [0001370042] | |
| SC 13G | [0001370042] | |
| 13F-HR | [0001440771] | |
| 3 | [0001440771] | |
| 4 | [0001440771] | |
| SC 13G | [0001440771] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 213800AIP1E4A547KD30 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Chiasma Inc CHMA
Common Stock
|
2021-08-05 | Disposed to issuer | 6,770,000 | ||
|
Novelion Therapeutics Inc NVLNF
Common Stock
|
2019-12-12 | Buy | 1,000 | $0.70 | 700 |
|
Novelion Therapeutics Inc NVLNF
Common Stock
|
2019-12-11 | Buy | 40 | $0.69 | 28 |
|
Novelion Therapeutics Inc NVLNF
Common Stock
|
2019-12-10 | Buy | 5,202 | $0.69 | 3,589 |
|
Novelion Therapeutics Inc NVLNF
Common Stock
|
2019-12-09 | Buy | 4,500 | $0.70 | 3,150 |
|
Novelion Therapeutics Inc NVLNF
Common Stock
|
2019-12-06 | Buy | 40 | $0.70 | 28 |
|
Novelion Therapeutics Inc NVLNF
Common Stock
|
2019-12-05 | Buy | 5,160 | $0.70 | 3,612 |
|
Novelion Therapeutics Inc NVLNF
Common Stock
|
2019-11-22 | Buy | 89,845 | $0.75 | 67,384 |
|
Novelion Therapeutics Inc NVLNF
Common Stock
|
2019-10-11 | Buy | 100,000 | $0.65 | 65,000 |
|
Lpath Inc APEN
Warrant · derivative
|
2019-08-12 | Other | 1 | ||
|
Lpath Inc APEN
6.0% Convertible Debenture due 2024 · derivative
|
2019-08-12 | Buy | $2,775,000.00 | ||
|
Lpath Inc APEN
Common Stock
|
2019-08-12 | Other | 1,000,000 | ||
|
Lpath Inc APEN
Common Stock
|
2018-12-27 | Sell | 250,000 | $3.00 | 750,000 |
|
Lpath Inc APEN
Common Stock
|
2018-12-26 | Sell | 500,000 | $3.00 | 1,500,000 |
|
Lpath Inc APEN
Common Stock
|
2018-11-21 | Buy | 3,230 | $3.61 | 11,660 |
|
Lpath Inc APEN
Common Stock
|
2018-11-19 | Buy | 54,200 | $3.40 | 184,280 |
|
Lpath Inc APEN
Common Stock
|
2018-11-02 | Buy | 300,000 | $5.00 | 1,500,000 |
|
Lpath Inc APEN
Common Stock
|
2018-01-03 | Buy | 6,339 | $5.78 | 36,639 |
|
Lpath Inc APEN
Common Stock
|
2018-01-02 | Buy | 11,343 | $5.73 | 64,995 |
|
Lpath Inc APEN
Common Stock
|
2017-12-29 | Buy | 5,163 | $5.56 | 28,706 |
| showing 20 of 43 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
X Cubed Capital Management LLC
✚
|
MN | 184.0 M |
|
Open Door Investment Management Ltd
✚
|
CA | 183.4 M |
|
Smith Asset Management Group LP
✚
|
TX | 182.2 M |
|
Emmett Investment Management LP
✚
|
NY | 181.6 M |
|
Alpine Woods Capital Investors LLC
✚
|
NY | 180.6 M |
|
2E Capital Partners LP
✚
|
NY | 180.0 M |
|
Daventry Group LP
✚
|
NY | 179.9 M |
|
Arc24 Management LP
✚
|
NY | 179.7 M |
|
Gallo Partners LP
✚
|
179.0 M | |
|
Candelo Capital Management LP
✚
|
NY | 178.1 M |